A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients With Advanced, Incurable, Solid Tumors in Which the Target Kinases Are Linked to Disease Pathophysiology

Trial Profile

A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients With Advanced, Incurable, Solid Tumors in Which the Target Kinases Are Linked to Disease Pathophysiology

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Pexidartinib (Primary)
  • Indications Gastrointestinal stromal tumours; Giant cell tumour of tendon sheath; Solid tumours; Thyroid cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
    • 30 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
    • 06 Jun 2017 Results of association of MRI measures with patient-reported outcomes in patients with tenosynovial giant cell tumors (n=15) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top